1. Malaysia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kotra Industries Bhd.

Kotra Industries Bhd.

MMYX:KOTRA
3.70
MYR
0.00
(0.00%)
13.59P/E
Dec 01Next Earn
Kotra Industries Bhd.
MYX:KOTRA
(Bursa Malaysia)

Recent

price

3.70

P/E

ratio

13.59

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
MYR
0.91
1.03
1.03
1.12
1.1
1.21
1.25
1.34
1.24
1.19
1.08
1.41
1.64
1.53
1.56
- -
1.57
Revenue per Share
-0.02
0.01
0.03
0.04
0.01
0.06
0.09
0.12
0.16
0.2
0.17
0.42
0.44
0.3
0.29
- -
0.27
Basic EPS, GAAP
0.05
-0.02
0.07
0.05
0.16
0.12
0.23
0.22
0.18
0.33
0.28
0.38
0.27
0.11
0.14
- -
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.02
0.04
0.06
0.09
0.07
0.17
0.26
0.28
0.25
- -
0.09
Dividend per Share
0.81
0.82
0.85
0.9
0.92
0.99
1.07
1.14
1.2
1.31
1.4
1.65
1.83
1.86
1.89
1.94
1.94
Book Value per Share
0.81
0.82
0.85
0.9
0.92
0.99
1.07
1.14
1.2
1.31
1.4
1.65
1.83
1.86
1.89
1.94
1.94
Tangible Book Value per Share
124
124
128
132
132
132
133
133
139
145
148
148
148
148
148
- -
148
Basic Weighted Avg Shares
113
127
131
147
145
160
166
178
173
172
160
208
242
227
231
233
233
Sales/Revenue/Turnover
2.31
4.01
7.92
7.6
2.41
7.74
9.21
10.73
12.45
14.81
16.22
26.72
24.96
21.8
22.26
22.27
22.27
Operating Margin (%)
6
11
11
11
12
13
13
14
14
16
16
15
15
14
14
15
15
Depreciation Expense
-2
1
4
6
1
8
12
16
22
30
24
62
65
45
42
41
41
Net Income, GAAP
- -
4.75
3.71
1.82
10.02
1.32
1.01
0.97
- -
- -
7.17
- -
1.27
21.03
17.29
21.4
21.4
Effective Tax Rate (%)
-1.9
0.88
2.81
3.84
0.73
4.84
7.45
8.82
12.86
17.21
15.28
29.87
26.93
19.68
18.4
17.42
17.42
Profit Margin (%)
15
27
36
32
33
36
49
56
60
72
90
127
127
98
77
75
75
Working Capital
88
91
90
84
76
67
57
46
31
18
7
- -
- -
- -
2
23
23
LT Debt
101
102
108
119
122
131
142
153
172
190
206
244
271
275
280
288
288
Total Equity
- -
2.17
4.36
4.66
1.36
5.4
6.86
8.97
- -
- -
10.88
- -
22.93
14.27
15.15
13.54
13.54
Return on Invested Capital (%)
- -
3.81
4.99
5.75
3.43
6.44
8.24
9.58
- -
- -
11.26
- -
24.97
16.27
15.2
13.7
13.7
Return on Capital (%)
-2.1
1.11
3.51
4.99
0.88
6.14
9.07
10.67
13.64
16.33
12.31
27.56
25.32
16.32
15.29
14.29
14.29
Return on Common Equity (%)

Capital Structure

MYR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
2
LT Borrowings
24
24
23
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
148
148
148
Market Capitalization
616
601
552

Working Capital

MYR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
141
134
131
Cash, Cash Equivalents & STI
49
44
35
Accounts Receivable, Net
39
38
39
Inventories
51
49
52
Total Current Liabilities
54
52
56
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
2
Deferred Revenue
- -
- -
- -

Growth Rates

MYR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.29%
7.09%
2.84%
Free Cash Flow
0.14%
-29.59%
-128.25%
Net Income, GAAP
26.22%
23.76%
-4.43%
Sales/Revenue/Turnover
4.34%
8.63%
0.97%
Total Cash Common Dividend
- -
39.35%
-13.73%

Quarterly Revenue

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
53
58
56
60
227
2025
66
54
58
52
231
2026
58
61
52
61
233

Quarterly Earnings Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.08
0.05
0.08
0.3
2025
0.07
0.07
0.08
0.07
0.29
2026
0.07
0.07
0.05
0.08
- -

Quarterly Dividends Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.13
- -
0.28
2025
- -
- -
- -
- -
0.25
2026
- -
- -
- -
0.09
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kotra Industries Berhad (KLCI: 0002) manufactures and distributes a range of pharmaceutical and healthcare products, including generic drugs, over-the-counter medications, and medical supplies. The company offers core products such as antibiotics, analgesics, vitamins and supplements, topical ointments, and herbal-based remedies under its own brands like Kotra Pharma and associated labels; it also provides contract manufacturing services for third-party pharmaceutical formulations and packaging solutions. Headquartered in Shah Alam, Selangor, Malaysia, and founded in 1979, Kotra Industries operates primarily in Southeast Asia, with distribution networks across Malaysia, Singapore, Indonesia, and export markets in the Asia-Pacific region, serving pharmacies, hospitals, clinics, and retail chains. The company focuses on the healthcare and consumer goods segments, targeting both institutional buyers and end-consumers seeking affordable, quality-assured medications. In recent developments, Kotra Industries expanded its production capacity through a strategic investment in a new manufacturing facility in 2024, enhancing output for high-demand generic antibiotics and sterile injectables to meet growing regional demand. The company formed a key distribution partnership with a leading Indonesian pharmaceutical distributor in early 2025, bolstering its market penetration in Southeast Asia's emerging markets. Additionally, Kotra launched a new line of bio-equivalent generic cardiovascular drugs in late 2024, alongside compliance upgrades to international GMP standards, positioning it for potential exports to regulated markets.